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BACKGROUND. A Phase II trial of irinotecan and cisplatin (IP) with early concur-
rent radiotherapy was performed in limited-disease small-cell lung cancer (LD-
SCLC) to evaluate the efficacy and toxicity.
METHODS. For untreated LD-SCLC patients, irinotecan (60 mg/m2, Days 1, 8, and
15) and cisplatin (40 mg/m2, Days 1 and 8) were repeated every 4 weeks for a
maximum of 6 cycles. Thoracic radiotherapy of 1.8 Gy/day was begun on Day 1
of the second chemotherapy cycle, up to a total of 45 to 54 Gy. Prophylactic
cranial irradiation (30 Gy in 10 fractions) was performed on patients with a com-
plete response (CR).
RESULTS. Thirty-three LD-SCLC patients were enrolled. The median age was 60
years and 31 patients had an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 to 1. Twelve (36.4%) patients had N3 disease. The response
rate was 87.9%, with a CR rate of 45.5%. At a median follow-up period of 27
months the median progression-free survival (PFS) and overall survival (OS) were
14.4 and 26.1 months, respectively, with 2-year PFS and OS rates of 26.8% and
54.9%. The dominating toxicity was neutropenia, with grade 3–5 of 81.8%. The
most common grade 3–5 nonhematologic toxicities were diarrhea (21.2%), ano-
rexia (21.2%), and fatigue (21.2%). Grade 3–5 radiation esophagitis and pneumo-
nitis occurred in 18.2% and 9.1% of patients, respectively. There were 2
treatment-related deaths from sepsis and radiation pneumonitis.
CONCLUSIONS. IP with early concurrent radiotherapy was effective and tolerable in
untreated LD-SCLC. Cancer 2007;109:1845–50. 2007 American Cancer Society.
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Small-cell lung cancer comprises about 20% of all lung malignan-cies and chemotherapy, rather than surgery, plays a pivotal role
in the treatment. Limited-disease small-cell lung cancer (LD-SCLC)
is defined as a disease confined to 1 hemithorax, which is generally
regarded as potentially curable. For LD-SCLC, to date, concurrent
chemoradiotherapy based on an etoposide/cisplatin (EP) regimen
and early radiation treatment has been the standard protocol since
the early 1990s.1–5 In spite of the good response of tumors to che-
moradiation, most patients still die as a result of systemic metasta-
sis, with a median survival of 17–27 months and a 2-year survival
rate of 33% to 54%.4–7 Therefore, more effective systemic chemo-
therapy regimens are needed to improve patient outcomes for LD-
SCLC.
Irinotecan, a topoisomerase I inhibitor, showed a synergistic ac-
tivity with cisplatin and seemed to be an active radiosensitizer in pre-
clinical studies.8,9 Moreover, for extensive-disease small-cell lung
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cancer (ED-SCLC), irinotecan was combined with cis-
platin and showed a better survival than an EP regi-
men in a prospective Phase III randomized study.10
With this background, we conducted a trial of iri-
notecan and cisplatin (IP) with early concurrent che-
moradiotherapy in order to evaluate the clinical
efficacy and toxicities in LD-SCLC.
MATERIALS AND METHODS
Eligibility Criteria
LD-SCLC was defined as a tumor confined to 1 hemi-
thorax where a primary tumor and regional nodes,
including ipsilateral supraclavicular nodes and contra-
lateral hilar/mediastinal nodes, were included. Patients
with ipsilateral pleural effusion were regarded as LD-
SCLC and enrolled in this study. Patients with LD-
SCLC were eligible if the following criteria were met: 1)
age 18 years; 2) histologically or cytologically proven
SCLC; 3) Eastern Cooperative Oncology Group (ECOG)
performance status of 2; 4) adequate bone marrow
(neutrophils 1.5 3 103/lL, platelets 100 3 103/lL,
and Hb 10.0 g/dL), renal (serum creatinine 1.5 3
upper normal limit), and liver function (serum biliru-
bin 1.5 3 upper normal limit and aspartate amino-
transferase [AST] and alanine aminotransferase [ALT]
1.5 3 upper normal limit); 5) no previous chemo- or
radiotherapy; and 6) no history of other malignancies
excluding nonmelanoma skin cancer or carcinoma in
situ of the uterine cervix. All the patients were required
to provide written informed consent and this protocol
was approved by the institutional ethics committee.
Treatment Protocol
For pretreatment staging, chest x-ray, chest and ab-
dominal computed tomography (CT) scan, and radi-
onuclide bone scan were conducted within 4 weeks
before enrollment. Brain magnetic resonance ima-
ging was performed only in symptomatic patients.
Irinotecan (60 mg/m2, 90-minute intravenous infu-
sion on Days 1, 8, and 15) and cisplatin (40 mg/m2,
60-minute intravenous infusion on Days 1 and 8)
were administered every 4 weeks for a maximum of
6 cycles. Modifications of doses and dosing sche-
dules were as follows: current chemotherapy was
omitted if grade 2 or worse hematologic toxicity
(neutropenia or thrombocytopenia) or grade 3–4
nonhematologic toxicity (eg, radiation pneumonitis
or esophagitis) was observed. The dose was reduced
at the subsequent week or cycle if hematologic toxic-
ity was grade 3–4 or nonhematologic toxicity was
grade 2 or worse. In detail, when grade 3 or 4 hema-
tologic toxicity was observed the next dose of irinote-
can was reduced to 50 mg/m2 or 40 mg/m2, re-
spectively, with an unchanged dose of cisplatin. In
the case of grade 2–3 nonhematologic toxicity, the
next doses were reduced to irinotecan/cisplatin of
50/30 mg/m2. In the case of grade 4 nonhematologic
toxicity, the next doses were reduced to irinotecan/
cisplatin of 40/20 mg/m2.
Once-daily thoracic radiotherapy (TRT) of 1.8 Gy/
day was begun on Day 1 of the second chemotherapy
cycle, up to a total of 45 to 54 Gy. Postchemotherapy
treatment volumes were used for radiotherapy. The tar-
get volume included the lung tumor and involved
lymph nodes with a margin of 1.5 cm. Prophylactic cra-
nial irradiation (PCI) with a total of 30 Gy in 10 frac-
tions was started in patients who achieved a complete
response (CR) within 2 weeks of completion of chemo-
therapy.
Granulocyte colony-stimulating factor (G-CSF)
was administered in the case of neutropenic fever.
Prophylactic G-CSF use was not permitted. Choliner-
gic symptoms including early diarrhea within 24
hours of irinotecan administration were treated with
atropine 1 mg intravenously. Loperamide was admi-
nistered for late diarrhea 1 day to several days after
irinotecan administration in the following manner:
4 mg at the first onset of diarrhea, then 2 mg every
2 hours until diarrhea stopped for 12 hours.
Follow-up of the patients was performed at 1-
month intervals for the first year, at 3-month inter-
vals for the second year, and at 6-month intervals
thereafter. Evaluations during these follow-up visits
included history taking, physical examination, com-
plete blood count, biochemical profile, chest x-ray,
chest CT, abdominal CT scan, and bone scan.
Endpoints Evaluation
Response was assessed, using chest CT scan, abdom-
inal CT scan, and/or bone scan after the first, third,
and sixth cycle of IP. Tumor response was classified
according to the Response Evaluation Criteria in
Solid Tumors11 as follows: CR, disappearance of all
target and nontarget lesions; partial response (PR), a
minimum of a 30% decrease in the sum of the long-
est diameter of target lesions; progressive disease
(PD), a minimum of a 20% increase in the sum of
the longest diameter of target lesions, appearance of
1 or more new lesions, or unequivocal progression of
existing nontarget lesions; stable disease (SD), nei-
ther sufficient shrinkage to qualify for PR nor suffi-
cient increase to qualify for PD. Patients who
achieved a response were required to take a confir-
mative CT scan at least 4 weeks later. Response dura-
tion was defined as the time from the first
documented day of response until disease progres-
sion or death. Progression-free survival (PFS) was
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defined as the time from commencement of the treat-
ment until disease progression or death. Overall sur-
vival (OS) was measured from the first date of the
treatment to death from any cause. Toxicity was
assessed weekly by history taking, physical examina-
tion, and complete blood count and monthly by bio-
chemical profile and chest x-ray during the treatment.
The toxicity was graded based on the National Cancer
Institute’s Common Toxicity Criteria v. 3.0.12
Stastistical Considerations
The sample size was calculated by the Fleming sin-
gle-stage design,13 based on an anticipated response
rate of 90%, threshold response rate of 65%, a 2-
sided significance level of 0.05, and a power of 0.8.
The minimum sample size was 28 and assuming a
10% of dropout rate, a final sample size was calcu-
lated to be 31 patients. All statistical calculations
were performed, using SPSS Windows program, v.
11.0 (SPSS, Chicago, Ill). Survival was estimated by
the Kaplan-Meier method. We measured the tumor
volumes before and after the first cycle of chemo-
therapy using CT scan and the paired t-test was used
for statistics.
RESULTS
Patients Characteristics
Thirty-three patients were enrolled in the study
between November 2002 and September 2005. The
median follow-up period was 27 months (range, 7.5–
41.4), as of April 20, 2006. All the patients had histo-
logically confirmed small cell carcinoma with clini-
cally limited stage. The median age was 60 years
(range, 38–76). Twenty-eight (84.8%) patients were
male. ECOG performance status was 0–1 in 31
(93.9%) and 2 in 2 (6.1%) patients. Twelve (36.4%)
patients had N3 disease: 9 had ipsilateral supracla-
vicular nodes involvement; 5 had contralateral hilar
nodes involvement; and 7 had contralateral mediast-
inal nodes involvement. Ipsilateral pleural effusion
was observed in 3 patients. The patient characteris-
tics are summarized in Table 1.
Response
Of the 33 patients, 2 were not assessable for
response: 1 case was due to treatment-related death
and the other was removed from the study because
of the adverse event after the first cycle of chemo-
therapy without response evaluation. The response
rate was 87.9% (29/33 patients), with a CR rate of
45.5% (15/33 patients) according to the intent-to-
treat analysis. The median response duration was
13.1 months (95% confidence interval [CI]: 6.6–19.6).
Progression-Free and Overall Survival
At a median follow-up period of 27.0 months (range,
7.5–41.4), 17 of the 33 patients experienced disease
progression. The median PFS was 14.4 months (95%
CI: 10.3–18.5). The 1- and 2-year PFS rates were
54.1% and 26.8%, respectively. Over the same follow-
up period, 16 of the 33 patients died and the median
OS was 26.1 months (95% CI: 9.0–43.2). The 1- and
2-year OS rates were 76.6% and 54.9%, respectively
(Fig. 1). Twelve patients died from disease progres-
sion and 2 from treatment-related sepsis and radia-
tion pneumonitis, respectively. The remaining 2
patients died from treatment-unrelated bacterial
pneumonia and a traffic accident, respectively. Pa-
tients with N3 disease had lower 2-year PFS (0% vs
43.5% in patients without N3; P ¼ .093) and OS (40.0%
vs 65.5% in patients without N3; P ¼ .037) rates.
Toxicity Profiles
The dominating toxicity was neutropenia, of which a
grade 3–5 was observed in 81.8% (27/33 patients). The
most common grade 3–5 nonhematologic toxicities
were diarrhea (21.2%), anorexia (21.2%), and fatigue
(21.2%). Grade 3–5 radiation esophagitis and pneumo-
nitis occurred in 6 (18.2%) and 3 (9.1%) patients,
respectively. There were 2 treatment-related deaths
from sepsis and radiation pneumonitis (Table 2).
Treatment Delivery and Dose Intensity
A total of 165 cycles of chemotherapy were delivered
and 20 (60.6%) of the 33 patients completed 6 cycles
of chemotherapy. Reasons for not completing chem-
otherapy were as follows: 5 disease progressions, 4
TABLE 1
Characteristics of the Patients
No. of patients (%)
Total no. of patients 33
Median age, y 60 (range, 36–76)
Sex
Men 28 (84.8)
Women 5 (15.2)
ECOG performance status
0 1 (3.0)
1 30 (90.9)
2 2 (6.1)
N3 nodes
Present 12 (36.4)
Absent 21 (63.6)
Pleural effusion
Present 3 (9.1)
Absent 30 (89.9)
ECOG indicates Eastern Cooperative Oncology Group.
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treatment-related adverse events, 3 self-refusals, and
1 pulmonary thromboembolism. Planned dose inten-
sities for irinotecan and cisplatin were 45 mg/m2/
week and 20 mg/m2/week, respectively. The median
relative dose intensities for irinotecan and cisplatin
were 0.65 (range, 0.33–0.96) and 0.80 (range, 0.46–
1.00), respectively. TRT was performed in 30 patients
(90.9%): 29 patients completed it with a median
dosage of 54.0 Gy (range, 45.0–64.8) and 1 patient
received a dosage of only 750 cGy because of self-re-
fusal. The remaining 3 patients could not receive
TRT due to early progression, death after first cycle
of chemotherapy, and self-refusal, respectively. PCI
was performed in 12 (80.0%) of the 15 CR patients.
Among the remaining 3 patients, 2 refused PCI and 1
died from radiation pneumonitis before PCI.
Patterns of First Failure and Salvage Chemotherapy
Among the 17 patients who had documented disease
progression, there were 5 locoregional failures alone,
5 distant metastases alone, and 7 both locoregional
and distant failures as the first failure. During the
whole follow-up period, brain metastasis occurred in
7 (21.2%) of 33 patients: 3 with PCI and 4 without
PCI (Table 3).
Twelve of the 17 patients who experienced dis-
ease progression received salvage chemotherapy.
Comparisons of Tumor Volumes at the Baseline
and After the First IP Chemotherapy
We compared tumor volumes at baseline and after
the first IP chemotherapy in 22 patients whose tumor
volumes could be measured by CT scan. Tumor
volumes were decreased in all but 1 patient after the
first IP chemotherapy. The median decrease of tumor
volume was 73.8% relative to the baseline volume
(P ¼ .000).
DISCUSSION
Topoisomerase I inhibitors and cisplatin showed
synergism in in vitro assays by increased interstrand
cross-linking (ICL), decreased DNA repair after ICL
formation, and enhanced topoisomerase I inhibitor
activity by cisplatin, as determined by the relaxation
of supercoiled DNA.8 Additionally, these 2 drugs do
FIGURE 1. Progression-free survival (PFS, dotted line) and overall survival
(OS, continuous line). Median OS duration, 26.1 months (95% confidence
interval [CI], 9.0-43.2); 2-year OS rate, 54.9%. Median PFS duration, 14.4
months (95% CI, 10.3-18.5); 2-year PFS rate, 26.8%.
TABLE 2
Toxicity Profiles (by Patient)
Toxicity
NCI-CTC grade
G1 G2 G3 G4 G5 G3 (%)
Hematologic
Neutropenia 0 6 17 9 1 27 (81.8)
Anemia 6 21 6 0 0 6 (18.2)
Thrombocytopenia 10 9 6 2 0 8 (24.2)
Nonhematologic
Diarrhea 7 5 6 1 0 7 (21.2)
Anorexia 4 16 7 0 0 7 (21.2)
Fatigue 0 12 7 0 0 7 (21.2)
Nausea 5 14 6 0 0 6 (18.2)
Esophagitis 3 12 6 0 0 6 (18.2)
Pneumonitis 7 5 1 1 1 3 (9.1)
Hyperbilirubinemia 0 1 1 0 0 1 (3.0)
Vomiting 2 6 1 0 0 1 (3.0)
Constipation 2 7 0 0 0 0 (0)
Neuropathy 1 3 0 0 0 0 (0)
NCI-CTC indicates the National Cancer Institute’s Common Toxicity Criteria.
TABLE 3
Patterns of First Failure
No. of patients (%)
Patients with progression 17 (100)
Site of progression
Locoregional 5 (29.4)
Locoregional and distant 7 (41.2)
Liver 2
Adrenal 2
Brain 2
Neck node 1
Distant 5 (29.4)
Brain 3
Bone 1
Neck node 1
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not overlap in their dominating toxicities. As such,
combinations of these 2 drugs have been tested in
several clinical trials since the late 1990s.10,14,15
Although a recent confirmative Phase III trial16
reported a different result in contrast to a Japanese
study reported by Noda et al,10 regarding an IP regi-
men compared with EP regimen in ED-SCLC, we had
been encouraged to conduct this trial to evaluate iri-
notecan plus cisplatin with early concurrent TRT in
LD-SCLC based on the positive result of the study in
ED-SCLC at that time. We were further prompted by
a Phase I study that showed tolerability of the IP reg-
imen with thoracic radiotherapy in LD-SCLC.17
The response rate (87.9%) and CR rate (45.5%) in
this study were similar or superior to rates in studies
using EP with TRT. Although this is a single-institu-
tion Phase II trial, the 2-year survival rate of 54.9%
with once-daily TRT is considerably more promising
over the previous results of the EP regimen-based
once daily or hyperfractionated concurrent radiother-
apy studies (Table 4).4,6,15,18,19 Moreover, in this trial
patients with more advanced disease were included.
For example, patients with ipsilateral pleural effusion
and/or contralateral mediastinal nodes that had been
exclusion criteria in other studies4,6,15,18,19 accounted
for 24.2% of the total patient population in this
study.
Two Phase I trials of IP-based concurrent che-
moradiotherapy have ever been reported: Yokoyama
et al.20 reported that they could not find a clinically
recommended dose of the IP regimen in unresect-
able stage III nonsmall-cell lung cancer because of
the toxicities such as leukopenia or diarrhea. In an
LD-SCLC trial reported by Oka et al.17 irinotecan/
cisplatin of 40/60 mg/m2 with split-course radiother-
apy was recommended. In our study we did not
want to compromise the systemic dose of irinote-
can/cisplatin in chemosensitive diseases such as
SCLC, just as with EP-based concurrent chemora-
diotherapy (CCRT). However, unlike the classic EP-
based CCRT protocol, in which radiotherapy was
administered from the first cycle of chemotherapy,
we started with a full dose of IP chemotherapy, with
once-daily radiotherapy administered on the first day
of the second cycle of chemotherapy. This chemora-
diotherapy schedule was aimed at reducing the tu-
mor volume after the first cycle of chemotherapy.
Actually, tumor volumes decreased by a median of
73.8% relative to baseline volume after the first IP
chemotherapy and finally would lead to a decreased
radiation field and toxicity. Although hyperfractio-
nated radiation has been a preferred strategy based
on a positive result in 1 large intergroup Phase III
study,6 TRT was administered once daily in this study
because the safety of hyperfractionated radiation
used concurrently with our IP regimen has not yet
been studied. Additionally, we adopted a strict dose
modification schedule so that we could continue the
radiotherapy to the end.
The median relative dose intensity was lower in iri-
notecan (0.65) vs cisplatin (0.80). The major reason for
irinotecan being delivered less than cisplatin was due
to neutropenia. However, TRT was completed in most
of the patients (87.9%). Although neutropenia was the
dominating toxicity, treatment-related death from
severe neutropenia was observed in only 1 patient. A
strict dose modification might improve this relatively
safe result. The rates of severe (grade 3) radiation
esophagitis (18.2%) and pneumonitis (9.1%) were com-
parable to the previous reports from EP-based concur-
rent chemoradiotherapy trials (Table 4).4,6,15,18,19
Diarrhea, which was rare in EP-based trials, was rela-
TABLE 4
Comparisons of Clinical Trials in Limited-Disease Small-Cell Lung Cancer
Author Year
Chemotherapy Thoracic radiotherapy Treatment outcome
No. Induction Concurrent
Dose,
Gy
Fraction,
Gy Timing
2-Year
PFS (%)
MST,
m
2-Year
OS (%)
Toxicity (Grade 3)
by patient (%)
Turrisi et al.6 1999 206 None EP q 3 wk 34 45 1.5 bid Concurrently with cycle 1 29 23 47 N(80), E(32), P(6); D(2.9)
Glisson et al.18 2000 67 None PIEo q 4 wk 34 45 1.5 bid Concurrently with cycle 1 30 23.7 50 N(66), E(43), P(13); D(1.5)
Takada et al.4 2002 114 None EP q 4 wk 34 45 1.5 bid Concurrently with cycle 1 28.9 27.2 54.4 N(88), E(9), P(0); D(2.6)
Schild et al.19 2004 130 EP q 4 wk 33 EP q 4 wk 33 50.4 1.8 daily Concurrently with cycle 4 31.3 20.6 44.3 N(>86), E(5), P(5); D(0)
131 EP q 4 wk 33 EP q 4 wk 33 48 1.5 bid Concurrently with cycle 4 30.8 20.6 44 N(>88), E(12), P(8); D(3)
Han et al.15 2005 35 IP q 3 wk 32 EP q 3 wk 32 45 1.5 bid Concurrently with cycle 3 36.1 25 53.9 N(100); E(29), P(9); D(0)
Current study 2006 33 IP q 4 wk 31 IP q 4 wk 35 54 1.8 daily Concurrently with cycle 2 26.8 26.1 54.9 N(81.8), E(18.2), P(9.1),
D(21.2)
N indicates number of patients; EP, etoposide plus cisplatin; PIEo, cisplatin plus ifosfamide plus oral etopside; IP, irinotecan plus cisplatin; q, every; wks, weeks; 2 Y PFS, 2 year progression-free survival; MST,
median survival time; OS, overall survival; Mo, months; NA, not available; In the toxicity column: Gr, grade; N, neutropenia; E, esophagitis; P, paeumonitis; L, leukopenia; D, death.
Irinotecan/Cisplatin With RT for LD-SCLC/Sohn et al. 1849
tively common, but was manageable in most cases
with antidiarrhetics.
Recently, an important association between ge-
netic polymorphism in the uridine diphosphate glu-
curonosyltransferase (UGT) 1A1 and irinotecan
toxicity has emerged.21 UGT1A1 is known to inacti-
vate the potent topoisomerase inhibitor SN-38, the
active metabolite of irinotecan.22 UGT1A1*28, a com-
mon polymorphism of UGT1A1, is significantly
higher in Caucasians than Asians.23 Therefore, the
toxicities of this regimen in the current study might
be more severe in Caucasians than Asian patients,
necessitating further trials for Caucasian patients.
Recently, a Phase II trial of irinotecan plus cisplatin
induction followed by concurrent twice-daily thoracic
irradiation with etoposide plus cisplatin chemotherapy
in patients with LD-SCLC was reported, with a promis-
ing efficacy (response rate, 97%; 2-year survival rate,
53.9%) and tolerability.15 Our study is the first Phase II
report that demonstrates that irinotecan/cisplatin-
based chemoradiotherapy is also effective and tolera-
ble in LD-SCLC.
In conclusion, IP with early concurrent radio-
therapy was effective and tolerable in untreated LD-
SCLC.
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